



About GeoVax Labs, Inc

GeoVax Labs, Inc. is a clinical-stage biotechnology company developing vaccines and immunotherapies against a wide range of infectious diseases and cancers using a novel, proprietary platform GV-MVA-VLP™.

September 25, 2020

Up-listed to Nasdaq and closed \$12.8M Public Offering - advancing high-value programs to clinical testing.

GeoVax Labs, Inc.
Nasdaq: GOVX

Recent Stock Price (9/30/20)	\$3.19
Market Capitalization	\$11.4M
Shares Outstanding	3.6M
Fiscal Year End	Dec 31

Investment Highlights



Proprietary Vaccine Platform — produces noninfectious Virus-Like-Particles (VLPs) in a vaccinated individual with an extensive, clinically-proven safety profile, highly durable immune response; potential for single-dose, highly-effective vaccines.

COVID-19 Four vaccine candidates under development including a single-dose “universal” coronavirus vaccine and a vaccine for high-risk populations; proceeding through animal challenge testing; and preparation for human clinical testing.

Immuno-oncology Program showing promising results; potential for multiple cancer indications; focused on advancing to clinical trials.

HIV Vaccine completed through Phase 2a; three clinical programs planned or in progress:

- Prevention (HVTN/NIH)
- Functional Cure (American Gene Technologies)
- Functional Cure (UCSF)

Preclinical Single-dose 100% protection demonstrated with Ebola, Marburg, and Sudan fever vaccines; U.S. Army funding Lassa program; non-dilutive funding for completion of animal testing.


Advancing Development Pipeline

		Target Identification	Preclinical Validation	Clinical Trials	
				Phase 1	Phase 2
Immuno-Oncology					
Solid Tumors					
HPV-associated Head and Neck Cancer					
Infectious Disease					
HIV (Preventive; HVTN)	GOVX-B11				
HIV (Functional Cure; UCSF; AGT)	GOVX-B01				
Lassa Fever	GEO-LM01				
Ebola, Marburg, Sudan	GEO-EM01				
Zika Virus	GEO-ZM02				
Malaria	GEO-MM01				
Coronavirus (COVID-19)	GEO-CM01				

COVID-19 Vaccine Program

Four vaccines GEO-CM01-04 designed; hamster challenge testing underway with CM01; animal testing for CM02-04 being scheduled.

Universal Coronavirus vaccine GEO-CM04 goal is to provide immunity to SARS-CoV-2 and seasonal coronavirus strains using defined T-cell epitopes "single-dose, universal coronavirus vaccine".



Advancing to Clinic Focused on accelerating development into clinical testing.


No FDA requirement for toxicology testing expected.

Scale up for Emergency Use Authorization readiness during Phase 1a/1b clinical trial.

Immuno-oncology Program GeoVax Concept for Cancer Immunotherapy

Triple-threat Approach

- 1 Tumor antigen specific immune responses will be stimulated
- 2 Immune inhibition is blocked with checkpoint inhibitors
- 3 Tumor cells are killed using an oncolytic virus



Tumor Regression

Stimulate MVA-VLP with tumor antigen to provoke immune system

Block Checkpoint inhibitor to reverse immune tolerance

Kill Achieve oncolysis using armed vaccinia virus

HIV Vaccine (GOVX-B11)

Most Clinically Advanced HIV Vaccine Program A prophylactic vaccine for the Clade B HIV, the subtype of HIV prevalent in the Americas, Australia, Japan and Western Europe; A vaccine for Clade C HIV, the subtype of HIV prevalent in the African continent and throughout ROW has been constructed.

Excellent Safety and Immunogenicity Phase 1 through 2a clinical trials completed.

Demonstrated superior antibody profile and durability compared to RV144 trial (Sanofi Phase 3 clinical trial).

Preventive Vaccine (GOVX-B11):

- Progressing to the next clinical trial (Phase 1; HVTN 132), evaluating GOVX-B11+novel booster, with support from HVTN/NIH

"Functional Cure" Programs Phase 1 trials planned or in progress.

- Collaboration with American Gene Technologies
- Collaboration with University of California San Francisco (UCSF)

Strong IP Protection

58
Granted
or pending patent
applications spread over
15 patent families

IR Contact: Tristan Traywick
CORE IR / 377 Oak Street
Garden City, NY 11530
investor@geovax.com